Syndax Pharmaceuticals Aktie [WKN DE: A2AFL6 / ISIN: US87164F1057]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Syndax Pharmaceuticals Inc

12.11.24		Syndax's Revumenib Trial Reports Positive Data In Relapsed/Refractory MNPM1 AML Patients (RTTNews)
19.09.24		Incyte: Phase 2 Trial Results Of Niktimvo In Chronic Graft-Versus-Host Disease Meet Primary Goal (RTTNews)
29.07.24		Syndax Pharma Says FDA Extended Drug Approval Decision Date For Revumenib By 3 Months (RTTNews)
14.06.24		Syndax Reports Updated Positive Data From Phase 1/2 Combination Trials Of Revumenib (RTTNews)
27.03.24		Syndax Announces FDA Priority Review Of NDA For Revumenib For Treatment Of R/R KMT2Ar Acute Leukemia (RTTNews)
28.02.24		Incyte's Axatilimab Receives FDA Priority Review For Chronic Graft-Versus-Host Disease Treatment (RTTNews)
02.01.24		Syndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
02.01.24		Syndax Highlights Recent Updates and Anticipated 2024 Milestones (PR Newswire)
19.12.23		Syndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares (PR Newswire)
15.12.23		Syndax Prices Public Offering Of About 10.8 Mln Shares At $18.50/share (RTTNews)
15.12.23		Syndax Pharma Prices Public Offering Of 10.8 Mln Shares At $18.50/Shr (RTTNews)
15.12.23		Syndax Announces Pricing of $200 Million Public Offering of Common Stock (PR Newswire)
14.12.23		Syndax Announces Proposed $150 Million Public Offering of Common Stock (PR Newswire)
12.12.23		Syndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting (PR Newswire)
11.12.23		Syndax Pharma Reveals Positive Data From Phase 1 Revumenib Combination Trials In Acute Leukemias (RTTNews)
11.12.23		Syndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials (PR Newswire)
04.12.23		Syndax to Host Investor Event to Discuss Axatilimab and Revumenib Data Updates at 65th ASH Annual Meeting (PR Newswire)
21.11.23		Syndax Announces Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Selected as Late-Breaking Presentation at the 65th ASH Annual Meeting (PR Newswire)
07.11.23		Syndax Announces Participation at Stifel Healthcare Conference (PR Newswire)
03.11.23		Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
02.11.23		Syndax Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update (PR Newswire)
02.11.23		Syndax Announces Updated Data Supporting Impressive Clinical Profile of Revumenib in Genetically-Defined Acute Leukemias to Be Presented at the 65th ASH Annual Meeting (PR Newswire)
02.11.23		Syndax Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting (PR Newswire)
26.10.23		Syndax to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 2, 2023 (PR Newswire)
24.10.23		Syndax to Initiate NDA Submission of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Under FDA's Real-Time Oncology Review Program (PR Newswire)
06.10.23		Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
02.10.23		Syndax Pharma AUGMENT-101 Trial Of Revumenib In Acute Leukemia Meets Key Goal (RTTNews)
02.10.23		Syndax Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stopped Early for Efficacy Following Protocol-Defined Interim Analysis (PR Newswire)
29.09.23		Syndax to Announce Topline Results from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia and Host an Investor Call on October 2, 2023 (PR Newswire)
01.09.23		Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
31.08.23		Syndax Announces Participation at the Citi 18th Annual BioPharma Conference (PR Newswire)
04.08.23		Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
03.08.23		Syndax Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update (PR Newswire)
25.07.23		Syndax to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast on August 3, 2023 (PR Newswire)
24.07.23		Syndax, Incyte Announce Positive Topline Results From AGAVE-201 Trial Of Axatilimab (RTTNews)
24.07.23		Syndax and Incyte Announce Positive Topline Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease (PR Newswire)
07.07.23		Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
02.06.23		Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
24.05.23		Syndax Announces Participation at Two Upcoming Investor Conferences (PR Newswire)
08.05.23		Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update (PR Newswire)
04.05.23		Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
01.05.23		Syndax to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 8, 2023 (PR Newswire)
13.04.23		Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
07.04.23		Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
30.03.23		Syndax Pharmaceuticals Announces Appointment of Neil Gallagher, M.D., Ph.D. as President, Head of Research and Development (PR Newswire)
15.03.23		Syndax Pharmaceuticals Announces Two Publications in Nature of Data from the Phase 1 Portion of AUGMENT-101 in Acute Leukemia Patients (PR Newswire)
06.03.23		Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
28.02.23		Syndax Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update (PR Newswire)
21.02.23		Syndax to Announce Fourth Quarter and Year-end 2022 Financial Results and Host Conference Call and Webcast on February 28, 2023 (PR Newswire)
14.02.23		Syndax Announces Participation at Upcoming Investor Conferences (PR Newswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Solana Kurs Prognose: – 10 Prozent in einer Woche – Jetzt schnell verkaufen?

Stablecoin von Ripple steht kurz vor großen Listings: Alle Einzelheiten im Überblick!

EU-Abgeordnete fordert Bitcoin statt digitalem Euro - strategische Bitcoin-Reserve für die EU

Diese Aktien empfehlen Experten zu kaufen

Während Ethereum 10 Prozent verliert, knackt Flockerz 10 Millionen US-Dollar

APA - N A C H R I C H T E N Ü B E R B L I C K

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	13.01.2025 04:45
Kaufwert:	EUR
	Hinzufügen Speichern